GLP-1 'biohacking' claims on TikTok: what holds up?

What did @biohackwithbails actually say?

The creator made a case for tesofensine as a brain-based appetite suppressant, describing it as a triple reuptake inhibitor that affects dopamine, serotonin, and norepinephrine. She framed each neurotransmitter with a catchy label: dopamine as the "I wanted chemical," serotonin as the "I am satisfied chemical," and norepinephrine as the "let's go chemical." She also claimed tesofensine drives thermogenesis and distinguishes itself from GLP-1 drugs by working in the brain rather than the gut.

She repeatedly referred to the drug as "Tessa Fensine" and at one point compared it to "ratatouille" (meaning retatrutide, a GLP-1/GIP/glucagon tri-agonist). The comparison itself was reasonable in concept, even if the pronunciation made it hard to follow. She never mentioned dosing, which is notable given tesofensine has a very narrow therapeutic window.

Does the science back this up?

The core pharmacology is broadly accurate. Tesofensine is a triple monoamine reuptake inhibitor. The clinical trial record, however, is thin and complicated. The TIPO-1 trial (Astrup et al., 2008, The Lancet) showed meaningful weight loss at 0.5mg and 1mg doses but significant cardiovascular side effects including elevated heart rate and blood pressure. That safety data is completely absent from this video.

The neurotransmitter descriptions are simplified but not wildly wrong. Dopamine does play a role in reward-motivated eating behavior, as shown in research by Wang et al. (2001, The Lancet) linking dopamine D2 receptor availability to obesity. Serotonin's role in satiety is well-supported, particularly through 5-HT2C receptor pathways. Norepinephrine does contribute to thermogenesis via beta-adrenergic receptor activation in brown adipose tissue (Cannon and Nedergaard, 2004, Physiological Reviews). The problem is the video presents these mechanisms as clean and tidy when the reality is far more complicated and the side effect implications are ignored entirely.

What did they get wrong (or right)?

Credit where it is due: the GLP-1 versus tesofensine distinction is actually a reasonable one. GLP-1 agonists primarily slow gastric emptying and act on peripheral and central GLP-1 receptors to reduce appetite. Tesofensine works primarily through central monoaminergic pathways. Framing this as "gut versus brain" is oversimplified but not inaccurate as a starting point.

What is genuinely wrong or incomplete here is significant. First, calling norepinephrine activity purely beneficial ignores that it also raises heart rate and blood pressure, which is exactly why tesofensine's development stalled after Phase 2. Second, the thermogenesis description is technically real but framed as a bonus feature rather than a mechanism with cardiovascular cost. Third, the claim that tesofensine will "drastically decrease" food noise implies a certainty the clinical data does not support at safe doses. And fourth, comparing it favorably to retatrutide without noting that retatrutide has a substantially larger and more recent clinical evidence base is misleading by omission.

What should you actually know?

Tesofensine is not FDA-approved. It is available through compounding pharmacies in some markets, which means formulation, purity, and dosing consistency are not federally regulated the way branded medications are. Compounded tesofensine is not the same as a pharmaceutical-grade product from a clinical trial.

The TIPO-1 trial data showed that even modest doses produced clinically meaningful increases in heart rate, roughly 7 to 8 beats per minute on average. For someone with underlying cardiovascular risk factors, that is not a trivial number. Anyone using this compound should be under the supervision of a licensed clinician who can monitor cardiovascular markers, and that context is entirely absent from this video.

The neurotransmitter framing also matters because triple reuptake inhibitors affecting dopaminergic pathways carry dependency and abuse potential considerations that deserve mention. This is not a supplement. It is a pharmacologically active compound with a history of being investigated as an antidepressant before being repurposed for obesity.